Department of Histopathology, Medical University of Silesia, Katowice, Poland.
Pathol Res Pract. 2011 Apr 15;207(4):220-4. doi: 10.1016/j.prp.2011.01.008. Epub 2011 Feb 26.
The aim of our study was to identify and describe potential inconsistencies between two alternative staging systems of pancreatic neuroendocrine neoplasms (pNENs)--the European Neuroendocrine Tumor Society (ENETS) system (2006) and the American Joint Committee on Cancer/Union for International Cancer Control (AJCC-UICC) system (2010). To address this issue, we performed a retrospective clinico-pathological study of 50 cases of pNENs. We found 9 (18%) cases of ENETS/AJCC-UICC discrepancies regarding the primary tumor stage. They included 7 cases of T2/T3 disagreement and 2 cases of T3/T4 disagreement. In addition, we discussed the issue of potential T1/T2 discrepancy (however, we did not observe any such a case). Another inconsistency was related to the application of different stage prognostic groupings between both systems. In conclusion, the discrepancies between ENETS and AJCC-UICC staging systems for pNENs are relatively frequent and heterogeneous. We believe that they should be rigorously recognized. This is necessary for the evaluation of prognostic factors and the effectiveness of therapeutic options used in patients with pNENs.
我们的研究目的是确定和描述两种胰腺神经内分泌肿瘤(pNENs)分期系统之间的潜在差异——欧洲神经内分泌肿瘤学会(ENETS)系统(2006 年)和美国癌症联合委员会/国际抗癌联盟(AJCC-UICC)系统(2010 年)。为了解决这个问题,我们对 50 例 pNENs 进行了回顾性临床病理研究。我们发现了 9 例(18%)ENETS/AJCC-UICC 差异,涉及原发肿瘤分期。其中包括 7 例 T2/T3 不一致和 2 例 T3/T4 不一致。此外,我们还讨论了 T1/T2 差异的潜在问题(然而,我们没有观察到任何这种情况)。另一个不一致是与两个系统之间不同的预后分组应用有关。总之,ENETS 和 AJCC-UICC 分期系统之间的差异相对频繁且多样。我们认为应该严格识别这些差异。这对于评估 pNENs 患者的预后因素和治疗方案的有效性是必要的。